Abstract |
Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.
|
Authors | Xiu Feng Hu, Pei Xiang Xing |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 6
Issue 12
Pg. 1266-71
(Dec 2005)
ISSN: 1472-4472 [Print] England |
PMID | 16370393
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Ki-1 Antigen
- iratumumab
|
Topics |
- Animals
- Antibodies, Monoclonal
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Clinical Trials as Topic
- Drug Screening Assays, Antitumor
- Hodgkin Disease
(drug therapy, immunology)
- Humans
- Ki-1 Antigen
(immunology)
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, immunology)
|